Armada 14 PTA Catheter
VASCULAR
hamburger

TAKING YOU FURTHER

Redefining possibilities in below-the-knee therapy

REACH AND COMPATIBILITY

  • Catheter and balloon design combines flexibility and strength to prevent kinking in distal lesions
  • Armada® 14 has balloon diameters of 1.5, 2, 2.5, 3 and 4 mm
  • Armada® 14 XT has balloon diameters of 1.2, 1.5 and 2 mm
  • Lengths of 90 cm and 150 cm (Armada 14) and 145 cm (Armada 14 XT)
  • All sizes are 4F compatible

CROSSABILITY

  • Streamlined tip and a low profile balloon designed to enter and cross difficult lesions
  • Two layers of outer coating for outstanding durability and lubricity during long, complex cases

PERFORMANCE

  • Rapid balloon deflation time of 17 seconds
  • Flexible tungsten markers for smooth tracking through tortuous anatomy

Fast Deflation Times1

Armada 14 Time for Full Balloon Deflation from RBP

 

Low Balloon Profile1

Armada 14 Maximum Deflated Balloon Profile

 

1Product sizes tested: Armada® 14: 4.0 x 200 mm x 150 cm, Amphirion® Deep: 3.5 / 4.0 x 210 mm x 150 cm, NanoCrossTM: 3.5 / 4.0 x 210 mm x 150 cm, SAVVY® Long: 4.0 x 220 mm x 120 cm, Sterling® SL: 4.0 x 150 mm x 150 cm

Tests performed by and data on file at Abbott Vascular.

Specifications

Armada 14 Ordering Specifications

Size Matrix

Armada 14 Ordering Sizing Matrix

armada-14-pta-catheter-ordering-info
armada-14-pta-catheter-ordering-info

PRODUCT INFO

Our online product catalogs provide the very latest information available, right at your fingertips. Download catalogs by product family in PDF format, or view the entire Abbott Vascular inventory in Excel. Product barcodes enable direct scanning for easy reordering.

INDICATIONS AND IMPORTANT SAFETY INFORMATION

rx-only-logo Armada 14 PTA Catheter

INDICATIONS

The device is indicated to dilate stenoses in femoral, popliteal, infra popliteal and renal arteries and for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae. The 2.0 to 4.0 mm balloon diameters are also indicated for post dilatation of balloon-expandable stents up to 40 mm and self-expanding stents up to 80 mm in the vessels listed above.

CONTRAINDICATIONS

  • Inability to cross lesion with a guide wire
  • Use in the coronary arteries.

WARNINGS/PRECAUTIONS

  • This device should only be used by physicians who are experienced and have a thorough understanding of the clinical and technical aspects of PTA.
  • One-time use only – do not resterilize! This single use device cannot be reused on another patient, as it is not designed to perform as intended after the first usage. Changes in mechanical, physical, and/or chemical characteristics introduced under conditions of repeated use, cleaning, and/or resterilization may compromise the integrity of the design and/or materials, leading to contamination due to narrow gaps and/or spaces and diminished safety and/or performance of the device. Absence of original labeling may lead to misuse and eliminate traceability. Absence of original packaging may lead to device damage, loss of sterility, and risk of injury to patient and/or user.
  • Do not use if inner package is damaged or opened.
  • Employ aseptic techniques during removal from the package and during use.
  • Any use for procedures other than those indicated in these instructions is not recommended.
  • Use prior to the use by date.
  • Carefully inspect the catheter prior to use to verify that it has not been damaged during shipment and that its size, shape and condition are suitable for the procedure for which it is to be used.
  • Precautions to prevent or reduce blood clotting should be taken when any catheter is used.
  • Flush or rinse all products entering the vascular system with sterile isotonic saline or a similar solution via the guide wire access port prior to use. Consider the use of systemic heparinization.
  • When the system is introduced into the vascular system, it should be manipulated only under high quality fluoroscopy.
  • The Armada 14 PTA Catheter must always be introduced, moved and or withdrawn over a guide wire (max. 0.014″).
  • Never attempt to move the guide wire when the balloon is inflated.
  • Never use air or any gaseous medium to inflate the balloon.
  • Do not advance the Armada 14 PTA Catheter against significant resistance. The cause of resistance should be determined via fluoroscopy and remedial action taken.
  • The minimal acceptable sheath French size is printed on the package label. Do not attempt to pass the Armada 14 PTA Catheter through a smaller sized sheath introducer than indicated on the label.
  • The size of the inflated balloon should be selected not to exceed the diameter of the artery immediately distal, or proximal, to the stenosis.
  • Inflation in excess of the rated burst pressure may cause the balloon to rupture. Use of a pressure monitoring device is recommended.
  • If a distal protection device is used, follow the manufacturer’s instruction for use. Allow and maintain adequate distance between the Armada 14 PTA Catheter and the distal protection device to avoid engagement.
  • Rated burst pressure and balloon fatigue testing of the Armada 14 PTA balloons within deployed stents has demonstrated the following: The 2.0 to 4.0 mm balloon diameters can safely post-dilate balloon expandable stents up to 40 mm in length. The 2.0 to 4.0 mm balloon diameters can safely post-dilate self expanding stents up to 80 mm in length. The safety of using additional balloon diameters and/or lengths to post dilate stents has not been established.
  • When post-dilating stents, use a balloon length that is appropriate for the deployed stent length.

POTENTIAL COMPLICATIONS

The following complications may occur as a result of PTA, but may not be limited to:

  • Abrupt closure
  • Access site hematoma
  • Aneurysm
  • Angina
  • Arrythmias
  • Arteriovenous fistula
  • Bleeding complications which may require transfusion
  • Cerebral ischemia/transient ischemic attack (TIA)
  • Death
  • Embolism (air, tissue, thrombotic, systemic or device component)
  • Fever/pyrogenic reaction
  • Hypersensitivity or allergic reaction to contrast agents and drug reactions
  • Hypertension/hypotension
  • Infection
  • Ischemia, including tissue ischemia, steal syndrome and necrosis
  • Leg edema
  • Myocardial ischemia or infarction
  • Nausea and vomiting
  • Neuropathies or nerve injury
  • Occlusion
  • Organ failure (single, multiple)
  • Pain
  • Palpitations
  • Pseudoaneurysm
  • Renal failure/insufficiency
  • Restenosis
  • Stroke/cerebrovascular accident (CVA)
  • Vascular complications, including entry site, which may require vessel repair
  • Vascular thrombosis
  • Vessel injury, e.g. dissection, perforation
  • Vessel spasm

Prior to use, reference the Instructions for Use provided inside the product carton (when available) or at eifu.abbottvascular.com for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

rx-only-logo Armada 14 XT Percutaneous Transluminal Angioplasty (PTA) Catheter

INDICATIONS

The Armada 14 XT PTA Catheter is indicated to dilate stenosis in femoral, popliteal, infrapopliteal and renal arteries and for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae. The 2.0 mm to 5.0 mm balloon diameters are also indicated for post-dilatation of stents in the peripheral vasculature.

CONTRAINDICATIONS

The Armada 14 XT PTA Catheter is contraindicated for:

  • Inability to cross lesion with a guide wire

WARNINGS

This device is intended for one time use only.
DO NOT resterilize and / or reuse it, as this can compromise device performance and increase the risk of cross contamination due to inappropriate reprocessing.

Any use for procedures other than those indicated in these instructions is not recommended. Precautions to prevent or reduce clotting should be taken when any catheter is used.

The size of the inflated balloon should be selected not to exceed the diameter of the artery immediately distal, or proximal, to the stenosis.

Balloon pressure should not exceed the rated burst pressure (RBP). The RBP is based on results of in vitro testing. At least 99.9% of the balloons (with a 95% confidence) will not burst at or below their RBP. Use of a pressure-monitoring device is recommended to prevent overpressurization. To reduce the potential for vessel damage, the inflated diameter of the balloon should approximate the diameter of the vessel just proximal and distal to the stenosis.Do not use, or attempt to straighten, a catheter if the shaft has become bent or kinked; this may result in the shaft breaking. Instead, prepare a new catheter. Do not torque the catheter more than one (1) full turn. If a distal protection device is used, follow the manufacturer’s instruction for use. Allow and maintain adequate distance between the Armada 14 XT PTA Catheter and the distal protection device to avoid engagement.

Use only the recommended balloon inflation medium. Never use air or any gaseous medium to inflate the balloon.

When the catheter is exposed to the vascular system, it should be manipulated while under high quality fluoroscopic observation. Do not advance or retract the catheter unless the balloon is fully deflated under vacuum. If resistance is met during manipulation, determine the cause of resistance before proceeding.

Treatment of moderately or heavily calcified lesions increases the risk of acute closure, vessel trauma, balloon burst, balloon entrapment, and associated complications. If resistance is felt, determine the cause before proceeding. Continuing to advance or retract the catheter while under resistance may result in damage to the vessels and / or damage / separation of the catheter. In the event of catheter damage / separation, recovery of any portion should be performed based on physician determination of individual patient condition and appropriate retrieval protocol. In cases of extreme vessel tortuosity, it may be necessary to reposition the catheter in a straight segment of the vessel in order to allow guide wire exchange. Do not continue to use a catheter if excessive resistance is felt during guide wire exchanges. Instead, prepare a new catheter.

PRECAUTIONS

This device should only be used by physicians who are experienced and have a thorough understanding of the clinical and technical aspects of PTA.

Note the “Use by” date specified on the package. Inspect all product prior to use. Do not use if the package is open or damaged. Prior to angioplasty, the PTA catheter should be examined to verify functionality and ensure that its size is suitable for the specific procedure for which it is to be used.

Precautions to prevent or reduce clotting should be taken when any catheter is used. Flush or rinse all products entering the vascular system with sterile heparinized normal saline or a similar solution via the guide wire access port prior to use. Consider the use of systemic heparinization.

Never attempt to move the guide wire when the balloon is inflated. The minimal acceptable sheath / guiding catheter French size is printed on the package label. Do not attempt to pass the Armada 14 XT PTA Catheter through a smaller sized sheath / guiding catheter than indicated on the label. If the surface of the Armada 14 XT PTA Catheter becomes dry, wetting with heparinized normal saline will reactivate the coating. Do not reinsert the Armada 14 XT PTA Catheter into the coil dispenser after procedural use. Bench testing was conducted with 0.014" (0.36 mm) constant diameter guide wires to establish guide wire compatibility. If another type of guide wire is selected with a different dimensional profile, the compatibility (e.g., wire resistance) should be considered prior to use. The safety and effectiveness of this PTA balloon catheter for the treatment of in-stent restenosis (ISR) have not been established.

ADVERSE EVENTS

Possible adverse effects include, but are not limited to, the following:

  • Abrupt closure
  • Access site hematoma
  • Aneurysm
  • Angina
  • Arrhythmias
  • Arteriovenous fistula
  • Bleeding complications, which may require transfusion
  • Cerebral ischemia / transient ischemic attack (TIA)
  • Death
  • Embolism (air, tissue, thrombotic, systemic or device component)
  • Fever / pyrogenic reaction
  • Hypersensitivity or allergic reaction to contrast agents and drug reactions
  • Hypertension /hypotension
  • Infection
  • Ischemia, including tissue ischemia, steal syndrome, and necrosis
  • Leg edema
  • Myocardial ischemia or infarction
  • Nausea and vomiting
  • Neuropathies or nerve injury
  • Occlusion
  • Organ failure (single, multiple)
  • Pain
  • Palpitations
  • Pseudoaneurysm
  • Renal failure/ insufficiency
  • Restenosis
  • Stroke / cerebrovascular accident (CVA)
  • Vascular complications, including entry site, which may require vessel repair
  • Vascular thrombosis
  • Vessel injury, e.g. dissection, perforation
  • Vessel spasm

Prior to use, reference the Instructions for Use provided inside the product carton (when available) or at eifu.abbottvascular.com for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

AP2939949-WBU Rev. A

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?

false
accessibility
© 2016 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?